2009 JASN IMPACT FACTOR 7.689	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text (Rapid PDF) All Versions of this Article: ASN.2010010079v1 21/5/733    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sterns, R. H. Articles by Chennupati, S. Search for Related Content PubMed PubMed Citation Articles by Sterns, R. H. Articles by Chennupati, S.

Ion-Exchange Resins for the Treatment of Hyperkalemia: Are They Safe and Effective?

Rochester General Hospital and University of Rochester School of Medicine and Dentistry, Rochester, New York

Correspondence: Dr. Richard H. Sterns, Rochester General Hospital, 1425 Portland Avenue, Rochester, NY 14621. Phone: 585-922-4242; Fax: 585-922-4440; E-mail: richard.sterns{at}rochestergeneral.org

Sodium polystyrene sulfonate (SPS), an ion-exchange resin designed to bind potassium in the colon, was approved in 1958 as a treatment for hyperkalemia by the US Food and Drug Administration, 4 years before drug manufacturers were required to prove the effectiveness and safety of their drugs. In September 2009, citing reports of colonic necrosis, the Food and Drug Administration issued a warning advising against concomitant administration of sorbitol, an osmotic cathartic used to prevent SPS-induced fecal impaction and to speed delivery of resin to the colon, with the powdered resin; however, a premixed suspension of SPS in sorbitol, the only preparation stocked by many hospital pharmacies, is prescribed routinely for treatment of hyperkalemia. We can find no convincing evidence that SPS increases fecal potassium losses in experimental animals or humans and no evidence that adding sorbitol to the resin increases its effectiveness as a treatment for hyperkalemia. There is growing concern, however, that suspensions of SPS in sorbitol can be harmful. It would be wise to exhaust other alternatives for managing hyperkalemia before turning to these largely unproven and potentially harmful therapies.

This article has been cited by other articles:

				Is Kayexalate Effective for Hyperkalemia, and Is It Safe? Journal Watch Pediatrics and Adolescent Medicine, June 9, 2010; 2010(609): 1 - 1. [Full Text]

Copyright © 2009 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673